Related Experiment Videos
Preclinical and clinical studies of MMP inhibitors in cancer
A H Drummond1, P Beckett, P D Brown
1British Biotech Pharmaceuticals Limited, Oxford, United Kingdom. drummond@britbio.co.uk
Abstract:
The role of matrix metalloproteinases in tumor angiogenesis and growth is now well recognized for models of both human and animal cancer. Clinical studies currently under way with the prototype matrix metalloproteinase inhibitor, marimastat, will establish whether inhibitors of these enzymes are of benefit in the treatment of different types of human cancer. On chronic therapy in humans, marimastat induces a reversible tendinitis that can also be detected in certain animal species. This paper compares the ability of broad-spectrum and various types of selective matrix metalloproteinase inhibitors to induce tendinitis and to exhibit anticancer effects in an animal cancer model. Under conditions in which both systemic exposure and inhibitor potency are controlled, selective inhibitors are less pro-tendinitic, but are weaker anticancer agents than broad-spectrum agents such as marimastat. The clinical relevance of these findings is discussed.
Insights
Matrix metalloproteinase inhibitors show promise for cancer treatment, but broad-spectrum agents like marimastat cause more tendinitis than selective ones. Selective inhibitors are less toxic but also less effective anticancer agents.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) play a crucial role in tumor angiogenesis and growth in both human and animal cancer models.
- Clinical trials are evaluating MMP inhibitors, such as marimastat, for cancer therapy.
- Marimastat can cause reversible tendinitis in humans and animal models.
Purpose of the Study:
- To compare the efficacy of broad-spectrum and selective MMP inhibitors in treating cancer.
- To assess the potential of these inhibitors to induce tendinitis in an animal cancer model.
Main Methods:
- Utilized an animal cancer model to evaluate MMP inhibitors.
- Controlled for systemic exposure and inhibitor potency.
- Assessed both anticancer effects and the induction of tendinitis.
Main Results:
- Selective MMP inhibitors were less likely to cause tendinitis compared to broad-spectrum agents.
- Broad-spectrum MMP inhibitors, like marimastat, demonstrated stronger anticancer effects.
- Selective inhibitors were found to be weaker anticancer agents than broad-spectrum ones.
Conclusions:
- The choice between broad-spectrum and selective MMP inhibitors involves a trade-off between anticancer efficacy and the risk of tendinitis.
- Findings have implications for the clinical application of MMP inhibitors in cancer treatment.
- Further research is needed to optimize MMP inhibitor therapy for cancer patients.